| scholarly article | Q13442814 |
| retracted paper | Q45182324 |
| P50 | author | Paul Dent | Q73523499 |
| Ankita Patel | Q88347804 | ||
| P2093 | author name string | Paul B Fisher | |
| Steven Grant | |||
| Peter Atadja | |||
| Roberto R Rosato | |||
| Jorge A Almenara | |||
| Sarah S Kolla | |||
| Sanjay Amin | |||
| Stefanie K Hock | |||
| P2860 | cites work | Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress | Q24300945 |
| Identification of nucleophosmin as an NF-kappaB co-activator for the induction of the human SOD2 gene | Q24337067 | ||
| Histone deacetylases (HDACs): characterization of the classical HDAC family | Q24535587 | ||
| The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression | Q24548310 | ||
| Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls | Q24570128 | ||
| HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination | Q24670026 | ||
| Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. | Q28118359 | ||
| Duration of nuclear NF-kappaB action regulated by reversible acetylation | Q28215080 | ||
| Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases | Q28239642 | ||
| Regulation of NF-kappaB action by reversible acetylation | Q28264218 | ||
| Regulation and function of IKK and IKK-related kinases | Q28268930 | ||
| Signals from within: the DNA-damage-induced NF-kappaB response | Q28291658 | ||
| The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species | Q28349324 | ||
| Shared principles in NF-kappaB signaling | Q29547234 | ||
| ATM and related protein kinases: safeguarding genome integrity | Q29547735 | ||
| Nuclear factor-kappaB in cancer development and progression | Q29547879 | ||
| Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage | Q29614218 | ||
| Ubiquitin signalling in the NF-kappaB pathway | Q29616322 | ||
| Regulation and function of NF-kappaB transcription factors in the immune system | Q29616427 | ||
| Anticancer activities of histone deacetylase inhibitors | Q29616624 | ||
| Acetylation and deacetylation of non-histone proteins | Q29619636 | ||
| Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway | Q30310695 | ||
| Mutations in the promoter reveal a cause for the reduced expression of the human manganese superoxide dismutase gene in cancer cells. | Q31917763 | ||
| Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors | Q33697130 | ||
| How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex | Q33797139 | ||
| Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation | Q33863049 | ||
| The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). | Q33962748 | ||
| Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies | Q34349201 | ||
| Regulated nucleosome mobility and the histone code. | Q34364723 | ||
| CK2 Is a C-Terminal IκB Kinase Responsible for NF-κB Activation during the UV Response | Q46589615 | ||
| Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome | Q47928900 | ||
| Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. | Q52564601 | ||
| Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. | Q52579549 | ||
| Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis? | Q53608201 | ||
| NF-kappaB activation by combinations of NEMO SUMOylation and ATM activation stresses in the absence of DNA damage. | Q53609454 | ||
| Cell biology. The stress of finding NEMO. | Q53635232 | ||
| NF-kappaB-dependent MnSOD expression protects adenocarcinoma cells from TNF-alpha-induced apoptosis. | Q53969781 | ||
| Vorinostat | Q56002311 | ||
| Regulation of NF-κB Action by Reversible Acetylation | Q56603128 | ||
| NF-κB activation prevents apoptotic oxidative stress via an increase of both thioredoxin and MnSOD levels in TNFα-treated Ewing sarcoma cells | Q57662587 | ||
| Whither RNAi? | Q73456158 | ||
| Activation of NF-kappaB by HDAC inhibitor apicidin through Sp1-dependent de novo protein synthesis: its implication for resistance to apoptosis | Q83182110 | ||
| PIDD mediates NF-kappaB activation in response to DNA damage | Q34477303 | ||
| New regulators of NF-kappaB in inflammation | Q34858737 | ||
| Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor | Q35070323 | ||
| Evidence that reactive oxygen species do not mediate NF-kappaB activation | Q35160731 | ||
| Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation | Q35200617 | ||
| The IKK NF-kappa B system: a treasure trove for drug development | Q35621375 | ||
| Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha | Q35661962 | ||
| The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress | Q35950143 | ||
| The death domain kinase RIP has an essential role in DNA damage-induced NF-kappa B activation | Q35964780 | ||
| A pervasive role of ubiquitin conjugation in activation and termination of IkappaB kinase pathways | Q36089051 | ||
| Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies | Q36129533 | ||
| Ubiquitin, TAK1 and IKK: is there a connection? | Q36399446 | ||
| NF-kappaB activation by reactive oxygen species: fifteen years later | Q36488422 | ||
| Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control | Q36639688 | ||
| Beyond IkappaBs: alternative regulation of NF-kappaB activity | Q36790420 | ||
| Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. | Q36851742 | ||
| Histone deacetylase inhibitors: molecular mechanisms of action | Q36908440 | ||
| Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions | Q36982745 | ||
| NF-kappaB and cancer-identifying targets and mechanisms | Q36984251 | ||
| Base excision repair of oxidative DNA damage and association with cancer and aging | Q37090426 | ||
| Specificity protein 1-dependent p53-mediated suppression of human manganese superoxide dismutase gene expression | Q37093126 | ||
| Two-step cross-linking method for identification of NF-kappaB gene network by chromatin immunoprecipitation. | Q38318340 | ||
| TRAF2 suppresses basal IKK activity in resting cells and TNFalpha can activate IKK in TRAF2 and TRAF5 double knockout cells | Q39857832 | ||
| ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia | Q39905532 | ||
| DNA-binding activity of NF-kappaB and phosphorylation of p65 are induced by N-acetylcysteine through phosphatidylinositol (PI) 3-kinase | Q39957062 | ||
| Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. | Q40077063 | ||
| Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer | Q40200801 | ||
| Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia | Q40219923 | ||
| PIASy mediates NEMO sumoylation and NF-kappaB activation in response to genotoxic stress. | Q40244068 | ||
| Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli | Q40312088 | ||
| Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation | Q40383692 | ||
| IkappaBalpha (inhibitory kappaBalpha) identified as labile repressor of MnSOD (manganese superoxide dismutase) expression | Q40522213 | ||
| Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer | Q40937865 | ||
| Tumor necrosis factors: developments during the last decade. | Q41020160 | ||
| Involvement of the ATR- and ATM-dependent checkpoint responses in cell cycle arrest evoked by pierisin-1. | Q42038207 | ||
| The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. | Q42163084 | ||
| An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells | Q44578401 | ||
| Involvement of histone H1.2 in apoptosis induced by DNA double-strand breaks | Q44593627 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| NF-κB | Q411114 | ||
| P304 | page(s) | 10064-10077 | |
| P577 | publication date | 2010-01-11 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway | |
| P478 | volume | 285 |
| Q39248784 | A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)). |
| Q40076402 | ATM is required for SOD2 expression and homeostasis within the mammary gland. |
| Q38769962 | Activating Transcription Factor 3 Expression as a Marker of Response to the Histone Deacetylase Inhibitor Pracinostat |
| Q35982670 | Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim |
| Q39395916 | CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells |
| Q35206717 | Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo |
| Q44558952 | Could interleukin-15 potentiate histone deacetylase inhibitor effects in haematological malignancy? |
| Q37995692 | DNA damage-dependent NF-κB activation: NEMO turns nuclear signaling inside out. |
| Q41808915 | Deacetylase inhibitors - focus on non-histone targets and effects |
| Q50456044 | Dimeric but not monomeric α-lactalbumin potentiates apoptosis by up regulation of ATF3 and reduction of histone deacetylase activity in primary and immortalised cells. |
| Q30424831 | Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors |
| Q35975127 | Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy |
| Q38572911 | Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments |
| Q42823841 | HDAC inhibitor-induced activation of NF-κB prevents apoptotic response of E1A+Ras-transformed cells to proapoptotic stimuli |
| Q37962333 | HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications |
| Q38054222 | HDAC inhibitors: roles of DNA damage and repair |
| Q35423449 | High throughput short interfering RNA (siRNA) screening of the human kinome identifies novel kinases controlling the canonical nuclear factor-κB (NF-κB) activation pathway |
| Q37812656 | Histone Deacetylase Inhibitors: Recent Insights from Basic to Clinical Knowledge & Patenting of Anti-Cancer Actions |
| Q33866592 | Histone acetyltransferases are crucial regulators in NF-κB mediated inflammation. |
| Q28076052 | Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation |
| Q33983255 | Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights |
| Q41046024 | Histone deacetylase inhibitors activate NF-κB in human leukemia cells through an ATM/NEMO-related pathway |
| Q38054227 | Histone deacetylase inhibitors and rational combination therapies |
| Q38422239 | Histone deacetylase inhibitors: potent anti-leukemic agents |
| Q37821337 | Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect |
| Q35859525 | IPO3-mediated Nonclassical Nuclear Import of NF-κB Essential Modulator (NEMO) Drives DNA Damage-dependent NF-κB Activation |
| Q53289378 | Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells |
| Q34205025 | Inhibiting NF-κB activation by small molecules as a therapeutic strategy |
| Q35782878 | LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism |
| Q38054220 | Mechanisms of resistance to histone deacetylase inhibitors |
| Q38109241 | Metalloporphyrins as therapeutic catalytic oxidoreductants in central nervous system disorders. |
| Q64064359 | MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines |
| Q37966563 | New insights into the roles of ATM and DNA-PKcs in the cellular response to oxidative stress |
| Q34458018 | Novel approaches in anaplastic thyroid cancer therapy |
| Q42659391 | Novel biomolecule lycopene-reduced graphene oxide-silver nanoparticle enhances apoptotic potential of trichostatin A in human ovarian cancer cells (SKOV3). |
| Q35347865 | Nuclear initiated NF-κB signaling: NEMO and ATM take center stage |
| Q38645501 | Oxidative Stress Gene Expression Profile Correlates with Cancer Patient Poor Prognosis: Identification of Crucial Pathways Might Select Novel Therapeutic Approaches. |
| Q38081475 | Peptide based macrocycles: selective histone deacetylase inhibitors with antiproliferative activity |
| Q37603936 | Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells |
| Q33425333 | Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics. |
| Q33962243 | Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells. |
| Q26740191 | Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy |
| Q36412841 | Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway |
| Q42647696 | Simultaneous NF-κB inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo. |
| Q38165621 | Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases. |
| Q35592352 | Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2. |
| Q37326878 | Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors |
| Q57712790 | Targeting transcription factor lysine acetylation in inflammatory airway diseases |
| Q31040364 | Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies. |
| Q36876973 | The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. |
| Q34707136 | The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma |
| Q53151459 | The inhibitor of histone deacetylases sodium butyrate enhances the cytotoxicity of mitomycin C. |
| Q33694349 | YY1 is indispensable for Lgr5+ intestinal stem cell renewal |
Search more.